Vorasidenib
VORANIGO
Isocitrate Dehydrogenase 1 Inhibitor
NADAC/unit
N/A
No Shortage
Tier 1: 35.9%
PA Req: 198.8%
VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isoc....
Generic Manufacturers
SERVIER PHARMACEUTICALS LLC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.